TROPION-Breast02: Datopotamab Deruxtecan for Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer.
FUTURE ONCOLOGY（2023）
Key words
antibody-drug conjugate (ADC),datopotamab deruxtecan (Dato-DXd),PD-1/PD-L1,triple-negative breast cancer,Trophoblast cell surface antigen 2 (TROP2)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined